在肿瘤学临床试验中促进全球健康公平。

IF 29.7 1区医学 Q1 ONCOLOGY Cancer discovery Pub Date : 2024-09-24 DOI:10.1158/2159-8290.CD-24-1288

{"title":"在肿瘤学临床试验中促进全球健康公平。","authors":"","doi":"10.1158/2159-8290.CD-24-1288","DOIUrl":null,"url":null,"abstract":"Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global \"hub-and-spoke\" network model to expand access to and accelerate clinical trials, thus ending cancer as a major cause of death in this lifetime.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1-OF7"},"PeriodicalIF":29.7000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advancing Global Health Equity in Oncology Clinical Trial Access.\",\"authors\":\"\",\"doi\":\"10.1158/2159-8290.CD-24-1288\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global \\\"hub-and-spoke\\\" network model to expand access to and accelerate clinical trials, thus ending cancer as a major cause of death in this lifetime.\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\" \",\"pages\":\"OF1-OF7\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-1288\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-1288","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

尽管业界对肿瘤研发的投资呈指数级增长，每年投入超过 800 亿美元，但全球临床试验的患者注册率仍低于 5%。我们的多方利益相关者国际癌症联盟设想通过全球 "枢纽-辐条 "网络模式进行能力建设，实现生态系统转型，以扩大临床试验的可及性并加快临床试验的进程，从而终结癌症这一主要致死原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Advancing Global Health Equity in Oncology Clinical Trial Access.

Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global "hub-and-spoke" network model to expand access to and accelerate clinical trials, thus ending cancer as a major cause of death in this lifetime.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.